Open Access Archives | Page 2 of 5

Oncotarget News

Oncotarget

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells

July 26, 2022

CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.”BUFFALO, NY- July 26, 2022 – A new research paper was... read more

Oncotarget

Oncotarget | Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

July 19, 2022

Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes.”BUFFALO, NY- July 19, 2022 – A new research paper was published in&... read more

Oncotarget

Oncotarget | New Oncology-Focused Papers Published in Volume 13

June 23, 2022

BUFFALO, NY- June 23, 2022 – At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in yearly volumes. As of June 23, 2022, Oncotarget has... read more

PRESS RELEASE: Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

Oncotarget

Impact Journals Sponsors 2022 Ride For Roswell

June 14, 2022

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.BUFFALO, NY- June 14, 2022 – The&... read more

Oncotarget

Impact Journals at AACR Annual Meeting 2022

March 28, 2022

BUFFALO, NY-March 28, 2022 – Impact Journals publishes scholarly journals in biomedical sciences with a focus on all areas of cancer and aging research. Impact Journals will... read more

Oncotarget

Oncotarget’s Top 10 Most-Viewed Papers in 2021

January 21, 2022

Read the 10 most-viewed oncology-focussed papers on Oncotarget.com in 2021.—#10: Metformin and berberine, two versatile drugs in treatment of common metabolic diseasesAuthors: Haoran Wang, Chen... read more

Oncotarget

Testimonial: Dr. Dean Felsher

January 20, 2022

Below is a transcript of the testimonial from Dr. Dean Felsher from Stanford University School of Medicine, Departments of Medicine and Pathology and member of Oncotarget’s Founding Editorial Board,... read more

Oncotarget

Open-Access Oncotarget Shifts to Continuous Publishing

January 6, 2022

As of 2022, the peer-reviewed and open-access journal Oncotarget has shifted to continuous publishing.—BUFFALO, NY, January 6, 2022 – Since its inception in 2010, Oncotarget ... read more

Oncotarget

Testimonial: Dr. Jennifer Sheng

December 10, 2021

Dr. Jennifer Sheng from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center shares her experience publishing "Innovating and expanding weight loss strategies for breast cancer survivors" with Oncotarget.Dr. Jennifer... read more

Oncotarget

Testimonial: Dr. Gina Abdelaal

December 3, 2021

Dr. Gina Abdelaal from Northumbria University discusses her experience publishing “Reversing oncogenic transformation with iron chelation,” with Oncotarget.Dr. Gina AbdelaalI selected Oncotarget because I remember... read more